Newron Pharmaceutical receives third tranche of EIB loan

In:

Waste and water

Region:

Europe

Italy-based Newron Pharmaceutical has received Tranche 3 under its financing agreement with the European Investment Bank. The tranche consists of €7.5 million and will primarily be used to support the company’s development programs in diseases of the central nervous system.

The EIB loan - up to a total of €40 million - is backed by the European Fund for Strategic Investments. The first two tranches of the loan totalling €17.5 million were received by Newron in 2019.

In connection with Tranche 3, EIB has received warrants entitling it to purchase up to 151,344 ordinary shares of Newron at an exercise price of €9.25 per share.

View source

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating...

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the...

Life sciences: DFIs test a new frontier in health PPP

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even...

Must See

Green Sky SAF: An Egypt first with lending precedents

Perspective

04 June 2026

Green Sky SAF: An Egypt first with lending precedents

A landmark sustainable aviation fuel project in Egypt shows that commercial banks and local equity can get behind emerging transportation fuels. But shared experience on an earlier SAF financing helped assure a painless close.

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating deals, and learning to measure impact

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the development finance industry.

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even vaccine sovereignty is hard to bank without public risk-sharing, demand visibility and unusually credible developers.